Agarwal P and Semimul A .2018 .A comprehensive review on sustained release matrix tablets: a promising dosage form. UJPR, 3(6) : 49-54.
Aulton ME,Taylor KM ME .2017 .Aulton's Pharmaceutics E-Book: The design and manufacture of medicines. Elsevier Health Sciences, : 566-575.
Arévalo R,Maderuelo C .2019 .Identification of the critical variables for the development of controlled release matrix tablets: Factorial design approach. , 4(1) : 250.
Pharmacopoeia British .2009 .British Pharmacopoeia Commission. The Stationery Office Limited, : 6578-6585.
Bourne D ,Banker GS .2002 .Pharmacokinetics. Marcel Dekker, : 66-91.
Cao QR,Choi YW,Cui JH,Lee BJ .2005 .Effect of solvents on physical properties and release characteristics of monolithic hydroxypropylmethylcellulose matrix granules and tablets. Arch. Pharm. Res., 28(4) : 493-501.
Lobo Costa P,JMS Costa P .2001 .Modeling and comparison of dissolution profiles. Eur. J Pharm. Sci., 13(2) : 123-133.
Coughlin JM,Wang Y,Ambinder EB,Ward RE,Minn I,Vranesic M,Pomper MG M .2016 .In vivo markers of inflammatory response in recent-onset schizophrenia: A combined study using [11 C] DPA713 PET and analysis of CSF and plasma. Transl. Psychiatry, 6(4) : e777-e777.
Davoodi P,Lee LY,Xu Q,Sunil V,Sun Y,Soh S,Wang CH .2018 .Drug delivery systems for programmed and on-demand release. Adv. Drug Deliv. Rev., 132(10) : 104-138.
Dedania ZR,Dedania RR,Sheth NR,Patel JB,Patel B .2011 .Stability indicating HPLC determination of risperidone in bulk drug and pharmaceutical formulations. Int. J. Anal. Chem, : .
El-Masry SM,Helmy SA .2020 .Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles. Saudi Pharm. J., 28(12) : 1704-1718.
FDA U .1997 .Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER. , : 1-11.
Ghori MU,Ginting G,Smith AM,Conway BR .2014 .Simultaneous quantification of drug release and erosion from hypromellose hydrophilic matrices. Int. J. Pharm., 465(1-2) : 405-412.
Grant S and Fitton A .1994 .. Risperidone. Drugs, 48(2) : 253-273.
Hixson AW,Crowell JH .1931 .Dependence of reaction velocity upon surface and agitation. Ind. Eng. Chem, 23(8) : 923-931.
ICH .2003 .Q1A (R2)-Stability testing of new drug substances and products. International Conference on Harmonisation (ICH), : 1-24.
ICH I .2005 .Q2 (R1): Validation of analytical procedures: Text and methodology. , : .
Joshi SC .2011 .Sol-gel behavior of hydroxypropyl methylcellulose (HPMC) in ionic media including drug release. Mater., 4(10) : 1861-1905.
Kamboj S,Gupta GD,Oberoy J .2017 .Matrix tablets: An important tool for oral controlled release dosage form. Pharmainfo. Net., 7(6) : 1-9.
Katzung BG .2017 .Basic and clinical pharmacology 14th edition. McGraw Hill Professional, : 504-519.
Klancar U,Baumgartner S,Legen I,Smrdel P,Kampus NJ,Krajcar D,Markun B,Kocevar K B .2015 .Determining the polymer threshold amount for achieving robust drug release from HPMC and HPC matrix tablets containing a high-dose BCS class I model drug: in vitro and in vivo studies. AAPS. Pharm. Sci. Tech, 16(2) : 398-406.
Klancar U,Horvat M,Baumgartner S M .2012 .Correlating cellulose derivative intrinsic viscosity with mechanical susceptibility of swollen hydrophilic matrix tablets. AAPS. Pharm. Sci. Tech, 13(3) : 903-910.
Klancar U,Markun B,Baumgartner S,Legen I .2013 .A novel beads-based dissolution method for the in vitro evaluation of extended release HPMC matrix tablets and the correlation with the in vivo data. AAPS. J., 15(1) : 267-277.
Kohrs NJ,Liyanage T,Venkatesan N,Najarzadeh A,Puleo DA .2019 .Drug delivery systems and controlled release. Elsevier, : 316-329.
Korsmeyer RW,Gurny R,Doelker E,Buri P,Peppas NA .1983 .Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm., 15(1) : 25-35.
Kumar M,Sharma P,Maheshwari R,Tekade M,Shrivastava SK,Tekade RK .2018 .Beyond the blood-brain barrier: Facing new challenges and prospects of nanotechnology-mediated targeted delivery to the brain. In: Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors, : 397-437.
Leon JD,Susce MT,Pan RM,Wedlund PJ,Orrego ML,Diaz FJ .2007 .A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry, 40(3) : 93-102.
Mannens GEERT,Huang ML,Meuldermans WILLEM,Hendrickx J,Woestenborghs ROBERT,Heykants JOSEPH .1993 .Absorption, metabolism, and excretion of risperidone in humans. Drug. Metab, 21(6) : 1134-1141.
O'hara T,Dunne A,Butler J,Devane J .1998 .A review of methods used to compare dissolution profile data. Pharmaceut. Sci. Tech, 1(5) : 214-223.
Patrick JS,Martin A .2017 .Martin's physical pharmacy and pharmaceutical sciences. , : 492-510.
Raghuvanshi S and Pathak K .2014 .Recent advances in delivery systems and therapeutics of cinnarizine: A poorly water soluble drug with absorption window in stomach. J. Drug. Deliv., : 1-15.
Shah RB,Tawakkul MA,Khan MA .2008 .Comparative evaluation of flow for pharmaceutical powders and granules. Aaps. Pharm. Sci. Tech, 9(1) : 250-258.
Shah VP,Tsong Y,Sathe P,Liu JP .1998 .In vitro dissolution profile comparison statistics and analysis of the similarity factor, f2. Pharm. Res., 15(6) : 889-896.
Svarstad BL,Shireman TI,Sweeney JK .2001 .Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. , 52(6) : 805-811.
Sweetman S. . .The Complete Drug Reference (Extra Pharmacopoeia-Martindale). Cloth, 20 : 1024-1027.
Thombre AG,Wu XY .2019 .Controlled release technology and design of oral controlled release dosage forms. Chemical engineering in the pharmaceutical industry: Drug Product Design. , : 381-407.
Jain Ummaheshwari R,NK Ummaheshwari R .2018 .Controlled and novel drug delivery systems. CBS Publishers and Distributors, 408 : .
USP35-NF30 U (2012b). United States . .Pharmacopeial. , : .
Shmeis Wang Z,RA Wang Z .2006 .Dissolution controlled drug delivery systems. Design of controlled release drug delivery systems. United States: McGraw-Hill, : 139-172.
Weiden PJ,Mackell JA,McDonnell DD .2004 .Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res., 66(1) : 51-57.